Kim Hyong sold $714K of ALHC

Kim Hyong (Chief Medical Officer) sold 35,951 shares of Alignment Healthcare, Inc. (ALHC) at $19.86 ($0.71M total) on 2026-06-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kim Hyong
Published Jun 15, 2026, 10:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALHC
Neutral
medium confidence
Mentioned
$ALHC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCNeutralLow
01

Why it matters

The newest fact is the specific sale size, price, and that it was executed under a pre-arranged 10b5-1 plan, which generally limits interpretive impact.

02

Market read

This provides a fresh, primary-source datapoint on insider activity but lacks any accompanying fundamental catalyst.

03

What to watch

Traders may over-weight insider sales; without accompanying guidance, trial, or contract news, the disclosure is unlikely to change valuation drivers.

Relevance 4/10Novelty 6/10Timing: SEC Form 4 filed 2026-06-15 (sale dated 2026-06-12)

Background

The article is an SEC Form 4 insider transaction disclosure for Alignment Healthcare, Inc.

Company-level read

Ticker impact

$ALHCNeutralMedium confidence
Context

Alignment Healthcare CMO Kim Hyong filed an open-market sale of 35,951 shares under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should be small unless accompanied by other company-specific catalysts.

Evidence & confidence

The disclosure is a routine Form 4 open-market sale with an explicitly pre-arranged 10b5-1 plan, which typically dampens interpretive value versus discretionary selling.

Market effects

No direct sector read-through; this is a single-company insider transaction without operational or regulatory updates.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than a negative view on fundamentals.

Key entities

  • Alignment Healthcare, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Kim Hyong

    Chief Medical Officer who sold 35,951 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALHCMedAI 8/10

Alignment Healthcare (ALHC) Q3 2026 Earnings Call Transcript

Alignment Healthcare (ALHC) reported Q3 2026 earnings, with revenue of $1.4B (up 37% YoY) and adjusted gross profit of $142M. The company lowered annual guidance due to higher costs, targeting adjusted gross profit of at least $575M and adjusted EBITDA of $100M. Membership grew 31% YoY to 301,200. ALHC is addressing cost pressures and investing in clinical programs for 2027 growth.

$ALHCMedAI 8/10

What Alignment Healthcare (ALHC) Said on Its Q3 Earnings Call

Alignment Healthcare (ALHC) reduced its 2026 outlook, expecting at least $5.25B revenue, $575M adjusted gross profit, and $100M adjusted EBITDA. Q4 forecasts include 305K membership, $1.32B revenue, and $104M gross profit. Management targets 20% top-line growth in 2027, with plans to enter new markets and improve care model scalability. Stars ratings and provider alignment remain focus areas.